A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 May 2015

At a glance

  • Drugs Mecobalamin (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 27 May 2015 Results presented at the 56th Annual Meeting of the Japanese Society of Neurology2, according to an Eisai media release.
    • 27 May 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology1, according to an Eisai media release.
    • 27 May 2015 According to an Eisai media release, the company has submitted an NDA for mecobalamin as a treatment for amyotrophic lateral sclerosis in Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top